Early Onset of Response to Zasocitinib (TAK-279), a Highly Selective and Potent TYK2 Inhibitor, Is Correlated With Modulation of TYK2 Signaling and Disease Pathway Biomarkers in Patients With Moderate-to-Severe Plaque Psoriasis

Review phase 2b trial data on zasocitinib in patients with moderate-to-severe plaque psoriasis.

ReachMD Healthcare Image
Media formats available
  • Completing the pre-test is required to access this content.
    Pre-Survey
    Completing the pre-survey is required to access this content.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free